A case of bile duct cancer with positive surgical margin obtaining lon

Discussion Board Forums Surgery, Resection & Transplant Treatment Options A case of bile duct cancer with positive surgical margin obtaining lon

Viewing 4 posts - 1 through 4 (of 4 total)
  • Author
    Posts
  • #56610
    Eli
    Participant

    Yeah, my recollection about S-1 could be wrong. I think it comes from this study:

    Recent progress and limitations of chemotherapy for pancreatic and biliary tract cancers
    http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3100481/

    Here’s what they say about S-1:

    Quote:
    S-1 is an oral fluoropyrimidine, consisting of tegafur, a prodrug of 5-FU, and two bio-modulators, 5-chloro-2,4-dihydroxypyridine and potassium oxonate, which maintains high serum 5-fluorouracil levels and reduces gastrointestinal toxicity. S-1 has demonstrated efficacy in a variety of solid tumors, especially in Asian patients.

    The bolded part seems to suggest that S-1 is more effective in Asian patients. Doesn’t mean that it’s not effective in Western patients. It might be effective, just not to the same extent.

    EDIT: Here’s a study that confirmed that the maximum dose of S-1 tolerated by Western patients is lower than the dose tolerated by Japanese patients.

    http://jco.ascopubs.org/content/23/28/6957.full

    #56609
    pcl1029
    Member

    Hi,
    If my info is correct. S1 will be available in the States in a couple years.and is now under studied by the FDA for its effectiveness as compare to Xeloda.

    Last year,when I attended the ASCO 2011 convention there was a poster about s1, and the gentleman on duty indicated that they will try to market S1 thru a larger drug company in the States. I will get more info about S1 in the up coming ASCO2012 convention.

    Basically S1 is like the Xeloda (Capecitabine) that is current available in Europe and in the States. these are the prodrug of 5FU taken by mouth.
    God bless.

    #56608
    Eli
    Participant

    Keep in mind, S-1 therapy is only used in Asia. Western hospitals don’t use it. Western patients can’t take it because of genetic differences. It’s either ineffective or causes bad reaction (don’t remember the exact details).

    #6204
    gavin
    Moderator

    A case of bile duct cancer with positive surgical margin obtaining long-term survival after s-1 monotherapy

    http://www.ncbi.nlm.nih.gov/pubmed/22241367?dopt=Abstract

Viewing 4 posts - 1 through 4 (of 4 total)
  • You must be logged in to reply to this topic.